The head of global supply chain at Sanofi, speaking at an industry event, outlined the company’s transformative journey towards becoming a leader in AI-driven operations within the biopharmaceutical sector. Central to this initiative is the goal of ensuring patients receive critical medications while navigating the complexities of modern supply chains. Every day, the focus remains on mitigating potential challenges to maintain a seamless flow of products to those in need.
Sanofi is currently undertaking a substantial digital transformation, with ambitions to emerge as the first biopharma company powered by AI at scale. This involves developing a “smart supply chain”—a comprehensive, data-driven system designed for enhanced visibility from suppliers to the end consumer. Notably, this approach has led to quantifiable improvements, including a 12% increase in service levels and a significant 14-point gain in cost-to-serve efficiency. Such advancements have arisen from the replacement of antiquated Excel-based workflows with more sophisticated Enterprise Resource Planning (ERP) systems and other advanced planning tools, which have collectively boosted operational visibility and responsiveness.
As part of this broader vision, Sanofi is making substantial investments aimed at reinforcing its manufacturing and research capabilities in the United States. A commitment of at least $20 billion by 2030 is set to create high-paying jobs across various states, mirroring a nationwide trend toward reshoring pharmaceutical production. This initiative underlines the critical role of the U.S. market, which constituted nearly half of Sanofi’s revenue in the first quarter of 2025.
Sustainability is another cornerstone of Sanofi’s operational strategy, with ambitious targets to reach carbon neutrality by 2030 and achieve net-zero greenhouse gas emissions by 2045. Since 2019, the company has successfully trimmed back its Scope 1 and 2 emissions by 47% and is on track to reduce Scope 3 emissions by 10%. In pursuit of these sustainability objectives, Sanofi is moving away from reliance on air freight, opting instead for more eco-friendly transport methods, such as rail and sea. In a forward-thinking move, the company has even begun exploring the use of sailing vessels for shipments, further reducing its environmental impact.
During her reflections on the event, the head of global supply chain emphasised the importance of collaborative engagement within the industry. She highlighted sessions dedicated to operational reimagination and sustainability, which not only reinforced Sanofi’s strategic direction but also prompted critical thinking about how to expedite progress in a rapidly changing healthcare landscape.
To further bolster its innovative edge, Sanofi has teamed up with OpenAI and Formation Bio in an initiative geared towards enhancing drug development through artificial intelligence. This partnership underscores a growing momentum within the pharmaceutical industry to harness AI for expedited development processes and cost efficiency. Additionally, the introduction of an AI-driven app named ‘plai,’ developed in collaboration with Aily Labs, showcases Sanofi’s commitment to integrating AI across all facets of its operations—from research and clinical trials to manufacturing. This app offers a comprehensive overview of the company’s activities, empowering teams to make informed decisions and drive productivity improvements across the value chain.
As Sanofi continues to evolve in this digital age, the interplay between innovation, sustainability, and patient-centric strategies stands out as a blueprint for the future, not only for the company but for the entire pharmaceutical industry.
Reference Map
- Paragraph 1: [1]
- Paragraph 2: [1]
- Paragraph 3: [2]
- Paragraph 4: [1]
- Paragraph 5: [1]
- Paragraph 6: [3], [4]
- Paragraph 7: [3], [6], [7]
- Paragraph 8: [1], [5]
Source: Noah Wire Services
Subscribe to Industry Updates
